Baltazar Gomez-Mancilla

Regional brain mGlu5 receptor occupancy following single oral doses of mavoglurant as measured by [11C]-ABP688 PET imaging in healthy volunteers

Simon M. Ametamey, Valerie Treyer, Alfred Buck, 2021, NeuroImage.

Chronic administration of AFQ056/Mavoglurant restores social behaviour in Fmr1 knockout mice

Ilse Gantois, Ben A. Oostra, Rob Willemsen, 2013, Behavioural Brain Research.

mGluR5 antagonists: discovery, characterization and drug development.

Baltazar Gomez-Mancilla, Fabrizio Gasparini, W. Spooren, 2008, Current opinion in drug discovery & development.

Epigenetic Modification of the FMR1 Gene in Fragile X Syndrome Is Associated with Differential Response to the mGluR5 Antagonist AFQ056

Janice Branson, Jacques S. Beckmann, Nouchine Hadjikhani, 2011, Science Translational Medicine.

Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome

Mark F. Bear, Eva Loth, Jacqueline N. Crawley, 2017, Nature Reviews Drug Discovery.

Treatment of Levodopa-Induced Dyskinesias : Results of 2 Randomized Controlled Trials

Daniela Berg, Maria Stamelou, Marc Vandemeulebroecke, 2011 .